Jury finds Parse Biosciences willfully infringed patents, awarding 10x Genomics $4.8M in damages.

A U.S. jury ruled that Parse Biosciences, now part of Qiagen, willfully infringed three patents licensed exclusively to Scale Biosciences, a 10x Genomics subsidiary. The patents, originally from Roche Sequencing Solutions, were upheld as valid and enforceable. The jury awarded 10x Genomics over $4.8 million in damages based on a 14% royalty rate for sales of infringing products from February 2021 to June 2026. 10x Genomics plans to seek additional damages and a permanent injunction to stop further infringement. This verdict underscores the importance of protecting intellectual property in advancing scientific innovation.